The following data also show that this inert approach to the older age group of individuals with diabetes in relation to prescribing SGLT2ins and GLP-1 RAs is not a consequence of their deliberate neglect of the elderly due to the shortened life expectancy in this subgroup but rather a consequence of insufficient clarity about the effects of these medications in older individuals, their cost–benefit profile, as well as the fear of harming them with medications with which they personally do not have sufficient experience. The gene discussed is GLP1R; the disease is diabetes mellitus.